Clinical Trial Update: Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer

View source ↗

Summary

This clinical trial update reports on PD-L1 expression in HER2-positive breast cancer and triple-negative breast cancer. The study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Ain Shams University | Conditions: Triple Negative Breast Cancer, HER2-positive Breast Cancer | Status: ACTIVE_NOT_RECRUITING